Evidence map›Paper›PMID 32641036›Full record

ReviewRespiratory research2020

Extracellular vesicles: novel communicators in lung diseases.

Aradhana Mohan, Stuti Agarwal, Matthias Clauss, Nicholas S Britt, Navneet K Dhillon

Open access · goldAbstract readReview
In one paragraph

Review in Respiratory research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 102 papers.

0numbers the graph read from it
0cells of the map it votes in
102citing papers in PubMed
7.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

102 citing papers in PubMed, 131 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review

42 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Aradhana MohanDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Kansas Medical Center, Mail Stop 3007, 3901 Rainbow Blvd, Kansas City, KS, 66160, USA.
Stuti AgarwalDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Kansas Medical Center, Mail Stop 3007, 3901 Rainbow Blvd, Kansas City, KS, 66160, USA.
Matthias ClaussDivision of Pulmonary, Critical Care, Sleep & Occupational Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Nicholas S BrittDepartment of Pharmacy Practice, University of Kansas School of Pharmacy, Lawrence, Kansas, USA.
Navneet K DhillonDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Kansas Medical Center, Mail Stop 3007, 3901 Rainbow Blvd, Kansas City, KS, 66160, USA. ndhillon@kumc.edu.
University of Kansas Medical Center · USIndiana University – Purdue University Indianapolis · USUniversity of Kansas · US

Funding

Understanding the mechanobiology of stem cells in a microengineered 3D cardiac tissue environment with cardiomyopathyP20GM103638 · NIGMS · UNIVERSITY OF KANSAS LAWRENCE · PI LUNTE, SUSAN M · 2012 to 2021
$22.1M
Using PCORnet to Expand the DS-CONNECT Cohort Through Healthcare System Recruitment, Incorporating Electronic Health Records, and Assessing Self-DeterminationU54HD090216 · NICHD · UNIVERSITY OF KANSAS LAWRENCE · PI COLOMBO, JOHN A. · 2016 to 2020
$6.2M
Extracellular Vesicles and and HIV/cocaine associated cardiopulmonary dysfunctionR01DA042715 · NIDA · UNIVERSITY OF KANSAS MEDICAL CENTER · PI DHILLON, NAVNEET KAUR · 2016 to 2020
$2.2M
Impact of Opiate abuse on HIV-mediated Pulmonary Vascular RemodelingR01HL129875 · NHLBI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI DHILLON, NAVNEET KAUR · 2016 to 2018
$1.5M
NHLBI NIH HHS R01 HL129875NHLBI NIH HHS R01HL129875NICHD NIH HHS U54 HD090216NIDA NIH HHS R01 DA042715NIDA NIH HHS R01DA042715NIGMS NIH HHS P20 GM103638
6 · The paper itself

Abstract

The lung is the organ with the highest vascular density in the human body. It is therefore perceivable that the endothelium of the lung contributes significantly to the circulation of extracellular vesicles (EVs), which include exosomes, microvesicles, and apoptotic bodies. In addition to the endothelium, EVs may arise from alveolar macrophages, fibroblasts and epithelial cells. Because EVs harbor cargo molecules, such as miRNA, mRNA, and proteins, these intercellular communicators provide important insight into the health and disease condition of donor cells and may serve as useful biomarkers of lung disease processes. This comprehensive review focuses on what is currently known about the role of EVs as markers and mediators of lung pathologies including COPD, pulmonary hypertension, asthma, lung cancer and ALI/ARDS. We also explore the role EVs can potentially serve as therapeutics for these lung diseases when released from healthy progenitor cells, such as mesenchymal stem cells.

Indexed as

Cell CommunicationExtracellular VesiclesBiomarkersCell-Derived MicroparticlesExosomesHumansLung DiseasesBiomarkers

Identifiers

PMID32641036
PMCPMC7341477
OpenAlexW3041098796

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.